We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-14.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$203M
AUM Growth
-$48.1M
Cap. Flow
-$4.46M
Cap. Flow %
-2.19%
Top 10 Hldgs %
43.02%
Holding
56
New
10
Increased
13
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$3.87M
2
INDP icon
Indaptus Therapeutics
INDP
+$3.69M
3
XOMA
Xoma
XOMA
+$3.63M
4
BPMC
Blueprint Medicines
BPMC
+$3.6M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$3.28M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.91M
2
MDXG icon
MiMedx Group
MDXG
+$7.15M
3
CMRX
Chimerix, Inc.
CMRX
+$6.42M
4
CEMP
Cempra, Inc.
CEMP
+$4.83M
5
MGNX icon
MacroGenics
MGNX
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 89.51%
2 Miscellaneous 10.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$11.8M 5.83%
310,000
-130,000
-30% -$6.42M
RARE icon
2
Ultragenyx Pharmaceutical
RARE
$2.59B
$10.6M 5.21%
110,000
– –
CEMP
3
DELISTED
Cempra, Inc.
CEMP
$10M 4.93%
360,000
-130,000
-27% -$4.83M
AXGN icon
4
Axogen
AXGN
$2.78B
$8.73M 4.3%
2,120,000
– –
GNMX
5
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8.28M 4.07%
1,058,400
+8,400
+0.8% +$65.1K
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
$7.95M 3.91%
200,000
+10,000
+5% +$621K
HROW icon
7
Harrow
HROW
$1.44B
$7.74M 3.81%
1,205,000
– –
ARIA
8
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$7.65M 3.76%
1,310,000
-190,000
-13% -$1.46M
TVTX icon
9
Travere Therapeutics
TVTX
$6.36B
$7.5M 3.69%
370,000
-90,000
-20% -$2.67M
KYNB
10
Kyntra Bio
KYNB
$32.4M
$7.12M 3.51%
13,000
– –
SUPN icon
11
Supernus Pharmaceuticals
SUPN
$2.57B
$6.45M 3.18%
460,000
-75,000
-14% -$1.39M
ZSPH
12
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$6.24M 3.07%
95,000
– –
TVRD
13
Tvardi Therapeutics
TVRD
$24M
$5.93M 2.92%
11,528
+2,084
+22% +$1.4M
CDXS icon
14
Codexis
CDXS
$182M
$5.49M 2.7%
1,620,000
-104,000
-6% -$388K
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.42M 2.67%
73,200
+23,200
+46% +$1.93M
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
$5.06M 2.49%
310,000
– –
GERN icon
17
Geron
GERN
$983M
$5.04M 2.48%
1,825,000
– –
NBIX icon
18
Neurocrine Biosciences
NBIX
$15.8B
$4.97M 2.45%
125,000
-20,000
-14% -$967K
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.25M 2.09%
105,000
– –
AFMD
20
DELISTED
Affimed
AFMD
$3.64M 1.79%
59,030
– –
INDP icon
21
Indaptus Therapeutics
INDP
$155M
$3.53M 1.74%
+281
New +$3.69M
AMRN
22
Amarin Corp
AMRN
$297M
$3.4M 1.67%
88,000
+300
+0.3% +$13.6K
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
$3.38M 1.66%
250,000
+135,937
+119% +$2.45M
TRIL
24
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.2M 1.57%
245,275
-4,725
-2% -$86.8K
TNXP icon
25
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opaleye Management held 56 positions worth $203M, down 19% from $251M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management's Q3 2015 filing shows 10 new, 13 increased, 12 reduced and 7 closed positions. Its largest new stake was TG Therapeutics: 260,000 shares worth $2.62M. The largest sale was Clovis Oncology, Inc., an estimated $7.91M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2015 buy was TG Therapeutics: 260,000 shares worth $2.62M.
  • Opaleye Management added most to Xoma in Q3 2015, an estimated $3.63M increase.
  • Opaleye Management's biggest Q3 2015 reduction was Chimerix, Inc., cutting an estimated $6.42M.
  • Opaleye Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $7.91M.
  • Opaleye Management's ten largest holdings make up 43% of its $203M portfolio in Q3 2015.
  • Opaleye Management opened 10 new positions and closed 7 in Q3 2015.
  • Opaleye Management's portfolio value fell 19% quarter-over-quarter to $203M.

Based on Opaleye Management's 13F filing for Q3 2015, filed 13 Nov 2015.